Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ORGO Organogenesis Holdings Inc
- Stocks
- Healthcare
- NASDAQ: ORGO
Price (delayed)
$3.06
Market cap
$388.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.17
Enterprise value
$320.27M
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's
Highlights
ORGO's debt has dropped by 63% year-on-year
The quick ratio has grown by 47% year-on-year and by 3.5% since the previous quarter
Organogenesis Holdings's gross profit has increased by 6% YoY but it has decreased by 5% QoQ
The company's revenue rose by 5% YoY but it fell by 4.8% QoQ
ORGO's equity is down by 13% YoY and by 8% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.organogenesis.com
Key stats
What are the main financial stats of ORGO
Market
Valuations
Earnings
Shares outstanding
126.85M
Market cap
$388.17M
Enterprise value
$320.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.6
Price to sales (P/S)
0.84
EV/EBIT
N/A
EV/EBITDA
245.79
EV/Sales
0.7
Revenue
$458.76M
Gross profit
$347.99M
Operating income
-$24.18M
Net income
-$15.88M
EBIT
-$24.18M
EBITDA
$1.3M
Free cash flow
-$7M
Per share
Balance sheet
Liquidity
EPS
-$0.17
EPS diluted
-$0.17
Free cash flow per share
-$0.06
Book value per share
$1.92
Revenue per share
$3.63
TBVPS
$3.38
Total assets
$467.39M
Total liabilities
$99.33M
Debt
$42.63M
Equity
$242.9M
Working capital
$203.11M
Debt to equity
0.18
Current ratio
4.12
Quick ratio
3.29
Net debt/EBITDA
-52.11
Margins
Efficiency
Dividend
EBITDA margin
0.3%
Gross margin
75.9%
Net margin
-3.5%
Operating margin
-5.3%
Return on assets
-4.4%
Return on equity
-7.8%
Return on invested capital
-7.7%
Return on capital employed
-6%
Return on sales
-5.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORGO stock price
How has the Organogenesis Holdings stock price performed over time
Intraday
-42.7%
1 week
-42.05%
1 month
-25%
1 year
34.21%
YTD
-4.38%
QTD
-29.17%
Financial performance
How have Organogenesis Holdings's revenue and profit performed over time
Revenue
$458.76M
Gross profit
$347.99M
Operating income
-$24.18M
Net income
-$15.88M
Gross margin
75.9%
Net margin
-3.5%
Organogenesis Holdings's gross profit has increased by 6% YoY but it has decreased by 5% QoQ
The company's revenue rose by 5% YoY but it fell by 4.8% QoQ
Price vs fundamentals
How does ORGO's price correlate with its fundamentals
Growth
What is Organogenesis Holdings's growth rate over time
Valuation
What is Organogenesis Holdings stock price valuation
P/E
N/A
P/B
1.6
P/S
0.84
EV/EBIT
N/A
EV/EBITDA
245.79
EV/Sales
0.7
The P/B is 64% below the 5-year quarterly average of 4.4 and 6% below the last 4 quarters average of 1.7
ORGO's equity is down by 13% YoY and by 8% QoQ
ORGO's P/S is 53% below its 5-year quarterly average of 1.8 and 7% below its last 4 quarters average of 0.9
The company's revenue rose by 5% YoY but it fell by 4.8% QoQ
Efficiency
How efficient is Organogenesis Holdings business performance
Dividends
What is ORGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORGO.
Financial health
How did Organogenesis Holdings financials performed over time
The current ratio has soared by 50% YoY and by 12% from the previous quarter
The quick ratio has grown by 47% year-on-year and by 3.5% since the previous quarter
ORGO's debt is 82% smaller than its equity
ORGO's debt has dropped by 63% year-on-year
The debt to equity has dropped by 57% year-on-year but it is up by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.